Literature DB >> 26099572

Biosimilar filgrastim (Zarzio®) vs. lenograstim (Myelostim®) for peripheral blood stem cell mobilization in adult patients with lymphoma and myeloma: a single center experience.

Francesco Marchesi1, Michele Vacca2, Svitlana Gumenyuk1, Annino Pandolfi2, Daniela Renzi1, Francesca Palombi1, Francesco Pisani1, Atelda Romano1, Antonio Spadea1, Francesco Ipsevich2, Susanna Santinelli3, Mafalda De Rienzo3, Elena Papa1, Marco Canfora4, Lamberto Laurenzi5, Maria Laura Foddai3, Luca Pierelli2, Andrea Mengarelli1.   

Abstract

Entities:  

Year:  2015        PMID： 26099572     DOI： 10.3109/10428194.2015.1063147

Source DB:  PubMed          Journal:  Leuk Lymphoma        ISSN： 1026-8022


× No keyword cloud information.
  3 in total

1.  Comparison of transplant outcomes and economic costs between biosimilar and originator filgrastim in allogeneic hematopoietic stem cell transplantation.

Authors:  Kaito Harada; Yuta Yamada; Tatsuya Konishi; Akihito Nagata; Toshiaki Takezaki; Satoshi Kaito; Shuhei Kurosawa; Masahiro Sakaguchi; Shunichiro Yasuda; Kosuke Yoshioka; Kyoko Watakabe-Inamoto; Aiko Igarashi; Yuho Najima; Takeshi Hagino; Hideharu Muto; Takeshi Kobayashi; Noriko Doki; Kazuhiko Kakihana; Hisashi Sakamaki; Kazuteru Ohashi
Journal:  Int J Hematol       Date:  2016-08-26       Impact factor: 2.490

2.  Evaluation of a biosimilar granulocyte colony-stimulating factor (filgrastim XM02) for peripheral blood stem cell mobilization and transplantation: a single center experience in Japan.

Authors:  Hideaki Yoshimura; Masaaki Hotta; Takahisa Nakanishi; Shinya Fujita; Aya Nakaya; Atsushi Satake; Tomoki Ito; Kazuyoshi Ishii; Shosaku Nomura
Journal:  J Blood Med       Date:  2017-01-24

Review 3.  Extrapolation in Practice: Lessons from 10 Years with Biosimilar Filgrastim.

Authors:  Pere Gascon; Andriy Krendyukov; Nicola Mathieson; Maja Natek; Matti Aapro
Journal:  BioDrugs       Date:  2019-12       Impact factor: 5.807
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.